Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°íÇü¾ÏÀÇ Ç×¾ÏÁ¦ Ä¡·áÈÄ ¹ß»ýÇϴ ȣÁß±¸°¨¼ÒÁõ¿¡ ´ëÇÑ Granulocyte Colony Stimulating Factor(G-CSF)ÀÇ È¿°ú The Effects of Granulocyte Colony Stimulating Factor on Neutropenia Induced by the Chemotherapy in the Solid Tumor Patient

´ëÇѾÏÇÐȸÁö 1994³â 26±Ç 1È£ p.144 ~ 150
¼Ò¼Ó »ó¼¼Á¤º¸
½Å»ó¿ø ³²¿ëÁø/ÃÖö¿ø/¼Û°ü±Ô/±èÁؼ®/±è¼ø´ö/±è¿µÈ«

Abstract


We evaluated the effect of granulocyte colony stimulating factor (G-CSF) to prevent chemotherapy induced neutropenia and fever development during neutropenic period. The twenty patients with solid tumor were treated with various cytotoxic
chemotherapeutic agents at least two cycles. The patients were given G-CSF 75¥ìg/day after 2nd cycle chemotherapy for least 14 consecutive days and clinical, laboratory results were compared to the first cycle's results.
Treatment with G-CSF resulted in increase of mean neutrophil count(320¡¾230/§§ vs 1030¡¾1020/§±), reduced the duration of neutropenic days(4.25 days vs 1.30 days, absolute neutrophil count less than 500/§§) and reduced the incidence of
neutropenic
fever(75% vs 25%).
The side effect of G-CSF was not so significant.
These results demonsrated that the use of G-CSF as an adjunct to chemotherapy with various solid cancer patients was well tolerated and led to reduction in the incidence of neutropenic fever; in the terms of incidence, duration, and severity of
neutropenia.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS